Clinical and toxicological consequences of the inductive potential of ethanol

European Journal of Clinical Pharmacology

Volumn 54, Issue 1, 1998, Pages 7-12

  Klotz, U ^a   Ammon, E ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b DIMDI   (Germany)

Author keywords

CYP2E1 Induction; Ethanol

Indexed keywords

ALCOHOL; CAFFEINE; CHLORZOXAZONE; CYTOCHROME P450; ENFLURANE; HALOTHANE; ISONIAZID; METHOXYFLURANE; PARACETAMOL; SEVOFLURANE; XENOBIOTIC AGENT;

ALCOHOL CONSUMPTION; ALCOHOL METABOLISM; DRINKING BEHAVIOR; DRUG METABOLISM; HUMAN; PRIORITY JOURNAL; REVIEW; XENOBIOTIC METABOLISM;

BIOTRANSFORMATION; CLINICAL TRIALS; CYTOCHROME P-450 CYP2E1; DRUG INTERACTIONS; ENZYME INDUCTION; ETHANOL; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 0031959220     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050412     Document Type: Review

References (71)

1. Spatzenegger M, Jaeger W (1995) Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 27: 397-417
2. Nelson DR, Koymans L, Kamataki T (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6: 1-42
3. Kroemer HK, Klotz U (1992) Glucuronidation of drugs. A reevaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet 23: 292-310
4. Burchel B, Brierley CH, Rance D (1995) Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 57: 1819-1831
5. Walter-Sack I, Klotz U (1996) Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 31: 47-64
6. Linnoila M, Mattila MJ, Kitchell BS (1979) Drug interactions with alcohol. Drugs 18: 299-311
7. Lane EA, Guthrie A, Linnoila M (1985) Effects of ethanol on drug and metabolite pharmacokinetics. Clin Pharmacokinet 10: 228-247
8. Agarwal D, Goedde H (1990) Alcohol metabolism, alcohol intolerance and alcoholism. Biochemical and pharmacogcnetic approaches. Springer, Berlin Heidelberg New York
9. Holford NHG (1987) Clinical pharmacokinetics of ethanol. Clin Pharmacokinet 13: 273-292
10. Koop DR (1992) Oxidative and reductive metabolism by cytochrome P4502E1. FASEB 6: 724-730
11. Park BK, Kitteringham NR, Pirmohamed M, Tucker GT (1996) Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol: 477-491
12. Koop DR, Tierney DJ (1990) Multiple mechanisms in the regulation of ethanol-inducible cytochrome P450IIE1. Bio Essays 12: 429-435
13. Ronis MJJ, Lindros KO, Ingelman-Sundberg M (1996) The CYP2E subfamily. In: Joannides C (ed). Cytochromes P450: metabolic and toxicological aspects. CRC. Boca Raton
14. Song BJ, Cederbaum AI (1996) Ethanol-inducible cytochrome P450 (CYP2E1): biochemistry, molecular biology, and clinical relevance: 1996 update. Alcohol Clin Exp Res 20: 138A-146A
15. Lindros KO (1997) Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. Gen Pharmac 28: 191-196
16. Guengerich FP, Kim D-H, Iwasaki M (1991) Role of human cytochrome P4502E1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4: 169-179
17. Ammon E, Schäfer C, Hofmann U, Klotz U (1996) Disposition and first-pass metabolism of ethanol in humans: is it gastric or hepatic and does it depend on gender? Clin Pharmacol Ther 59: 503-513
18. Peter R, Böcker R, Beaune P (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 IIE1. Chem Res Toxicol 3: 566-573
19. Kirn RB, O'Shea D, Wilkinson GR (1994) Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. Pharmacogenetics 4: 162-165
20. Vesell ES, Seaton TA, A-Rahim YI (1995) Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. Pharmacogenetics 5: 53-57
21. Kim RB, O'Shea D, Wilkinson GR (1995) Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 57: 645-655
22. Buchman K, Sarver JG (1996) Chlorzoxazone as a single sample probe for hepatic CYP2E1 activity in humans. Pharmacology 52: 169-177
23. Carriere V, Goasduff T, Ratanasavanh D (1993) Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol 6: 852-857
24. Gorski JC, Jones DR, Wrighton SA, Hall SD (1997) Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 27: 243-256
25. Girre C, Lucas D, Hispard E (1994) Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 47: 1503-1508
26. Zand R, Nelson SD, Slattery JT (1993) Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 54: 142-149
27. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH (1993) Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P4502E1. Clin Pharmacol Ther 53: 643-650
28. O'Shea D, Davis SN, Kim RB, Wilkinson GR (1994) Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 56: 359-367
29. Lucas D, Menez C, Girre C (1995) Decrease in cytochrome P450 2E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase. Alcohol Clin Exp Res 19: 362-366
30. Dilger K, Metzler J, Bode JC, Klotz U (1997) CYP2E1 activity in patients with alcoholic liver disease. J Hepatol 27: 1009-1014
31. George J, Murray M, Byth K, Farrell GR (1995) Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 21: 120-128
32. Gu L, Gonzales FJ, Kalow W, Tang BK (1992) Biotransformation of caffeine, paraxanthene, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2: 73-77
33. Waxman DJ, Lapenson DP, Aoyama T (1991) Steroid hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 290: 160-166
34. Patten C, Thomas PE, Guy R et al (1989) Cytochromes P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol 5: 549-555
35. Raucy JL, Lasker JM, Lieber CS, Black M (1989) Acetaminophen activation by human liver cytochromes P450 H E1 and P450 1A2. Arch Biochem Biophys 271: 270-283
36. Kharasch ED, Thummel KE (1993) Identification of cytochrome P4502E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 79: 795-807
37. Thummel KE, Kharasch ED, Podoll T, Kunze K (1993) Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab Dispos 21: 350-357
38. Kharasch ED, Thummel KE, Mautz D, Bosse S (1994) Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther 55: 434-440
39. Misra PS, Lefévre A, Ishii H, Rubin E, Lieber CS (1971) Increase of ethanol, meprobamate and pentobarbital metabolism after chronic ethanol administration in man and in rats. Am J Med 51: 345-351
40. Pelkonen O, Sotaniemi E (1982) Drug metabolism in alcoholics. Pharmacol Ther 16: 261-268
41. Hoyumpa A, Schenker S (1982) Major drug interactions. Effect of liver disease, alcohol, and malnutrition. Annu Rev Med 33: 113-149
42. Hoensch H (1987) Ethanol as enzyme inducer and inhibitor. Pharmacol Ther 33: 121-128
43. Engel G, Knebel NG, Hofmann U, Eichelbaum M (1996) Identification of human cytochrome P450 cnzymes involved in antipyrine metabolism. Clin Pharmacol Ther 59: 613-623
44. Sharer JE, Wrighton SA (1996) Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos 24: 487-494
45. Neuvonen PJ, Penttila O, Roos M, Tirkkonen J (1976) Effect of long term alcohol consumption on the halflife of tetracycline and doxycycline in man. Internat J Clin Pharmacol 14: 303-307
46. Kater RMH, Roggin G, Tobon F, Zieve P, Iber FL (1969) Increased rate of clearance of drugs from the circulation of alcoholics. Am J Med Sci 258: 35-39
47. Sandor P, Sellers EM, Dumbrell M, Khouw V (1981) Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. Clin Pharmacol Ther 30: 390-397
48. Sternebring B, Lidén A, Andersson K, Melander A (1992) Carbamazepine kinetics and adverse effects during and after ethanol exposure in alcoholics and in healthy volunteers. Eur J Clin Pharmacol 43: 393-397
49. Kater RMH, Tobon F, Iber FL (1969) Increased rate of tolbutamide metabolism in alcoholic patients. JAMA 207: 363-365
50. Iber FL (1977) Drug metabolism in heavy consumers of ethyl alcohol. Clin Pharmacol Ther 22: 735-742
51. Klotz U (1976) Pathophysiological and disease-induced changes in distribution volume: pharmacokinetic implications. Clin Pharmacokinet 1: 204-218
52. Slattery JT, Nelson SD, Thummel KE (1996) The complex interaction between ethanol and acetaminophen. Clin Pharmacol Ther 60: 241-246
53. Chien JY, Thummel KE, Slattery JT (1997) Pharmacokinetic consequences of induction of CYP2E1 by ligand estabilization. Drug Metab Dispos 25: 1165-1175
54. Pirttiaho HI, Sotaniemi EA, Ahlqvist J, Pitkänen U, Pelkonen RO (1978) Liver size and indices of drug metabolism in alcoholics. Eur J Clin Pharmacol 13: 61-67
55. Hoensch HP (1984) Enzyminduktion der Leber durch chronischen Alkoholismus als Risikofaktor der Hepatotoxizität. Z Gastroenterol 22: 1-8
56. Morimoto M, Hagbjörk A-L, Nanji AA (1993) Role of cytochrome P4502E1 in alcoholic liver disease pathogenesis. Alcohol 10: 459-464
57. Prescott LF, Newton RW, Swainson CP (1974) Successful treatment of severe paracetamol overdosage with cysteamine. Lancet 1: 582-592
58. McClain C, Kromhout JP, Peterson FJ, Holtzman JL (1980) Potentiation of acetaminophen hepatotoxicity by alcohol. JAMA 244: 251-253
59. Teschke R, Stutz G, Strohmeyer G (1979) Increased paracetamol induced hepatotoxicity after chronic alcohol consumption. Biochem Biophys Res Commun 91: 368-374
60. Zimmerman HJ, Maddrey WC (1995) Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 22: 767-773
61. Collins C, Starmer GA (1995) A review of the hepatotoxicity of paracetamol at therapeutic or near therapeutic dose levels, with particular reference to alcohol users. Drug Alcohol Rev 14: 63-79
62. Park BK, Kitteringham NR (1994) Effects of fluorine substitution on drug metabolism pharmacological and toxicological implications. Drug Metab Rev 26: 605-643
63. Tsutsumi R, Leso MA, Kim C (1990) Interaction of ethanol with enflurane metabolism and toxicity: role of P450IIE1. Alcohol Clin Exp Res 14: 174-179
64. Kharasch ED, Hankins DC, Thummel KE (1995) Human kidney methoxyfluran and sevoflurane metabolism. Anesthsiology 82: 689-699
65. Gut J, Christen U, Huwyler J (1993) Mechanisms of halothane toxicity: novel insights. Pharmacol Ther 58: 133-155
66. Kharasch ED, Hankins D, Mautz D, Thummel KE (1996) Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 347: 1367-1371
67. Manno M, Rezzadore M, Grossi M, Sbrana C (1996) Potentiation of occupational carbon tetrachloride toxicity by ethanol abuse. Hum Exp Toxicol 15: 294-300
68. Ingelman-Sundberg M, Johansson I, Yin H (1993) Ethanol-inducible cytochrome P450 2E1: genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. Alcohol 10: 447-452
69. Agarwal DP (1997) Molecular genetic aspects of alcohol metabolism and alcoholism. Pharmacopsychiatry 30: 79-84
70. Agúmdez J, Ladero J, Diaz-Rubio M, Benitez J (1996) Rsa 1 polymorphism at the cytochrome P4502E1 locus is not related to the risk of alcohol-related severe liver disease. Liver 16: 380-383
71. Savolainen VT, Pajarinen J, Perola M, Penntilä A, Karhunen PJ (1997) Polymorphism in the cytochrome P450 2E1 gene and the risk of alcoholic liver disease. J Hepatol 26: 55-61